PBH vs. IPAR, HLF, USNA, NUS, NATR, MED, VERU, EL, SNN, and BIO
Should you be buying Prestige Consumer Healthcare stock or one of its competitors? The main competitors of Prestige Consumer Healthcare include Interparfums (IPAR), Herbalife (HLF), USANA Health Sciences (USNA), Nu Skin Enterprises (NUS), Nature's Sunshine Products (NATR), Medifast (MED), Veru (VERU), Estee Lauder Companies (EL), Smith & Nephew SNATS (SNN), and Bio-Rad Laboratories (BIO).
Prestige Consumer Healthcare vs. Its Competitors
Prestige Consumer Healthcare (NYSE:PBH) and Interparfums (NASDAQ:IPAR) are both mid-cap personal products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.
Prestige Consumer Healthcare has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Comparatively, Interparfums has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.
In the previous week, Interparfums had 3 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 6 mentions for Interparfums and 3 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 1.78 beat Interparfums' score of 1.26 indicating that Prestige Consumer Healthcare is being referred to more favorably in the media.
Prestige Consumer Healthcare has higher earnings, but lower revenue than Interparfums. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Interparfums, indicating that it is currently the more affordable of the two stocks.
Prestige Consumer Healthcare has a net margin of 18.86% compared to Interparfums' net margin of 11.30%. Interparfums' return on equity of 17.62% beat Prestige Consumer Healthcare's return on equity.
Prestige Consumer Healthcare presently has a consensus target price of $93.33, suggesting a potential upside of 23.30%. Interparfums has a consensus target price of $162.00, suggesting a potential upside of 22.51%. Given Prestige Consumer Healthcare's higher probable upside, equities research analysts plainly believe Prestige Consumer Healthcare is more favorable than Interparfums.
Prestige Consumer Healthcare pays an annual dividend of $1.90 per share and has a dividend yield of 2.5%. Interparfums pays an annual dividend of $3.20 per share and has a dividend yield of 2.4%. Prestige Consumer Healthcare pays out 44.3% of its earnings in the form of a dividend. Interparfums pays out 62.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Interparfums has increased its dividend for 4 consecutive years. Prestige Consumer Healthcare is clearly the better dividend stock, given its higher yield and lower payout ratio.
99.9% of Prestige Consumer Healthcare shares are held by institutional investors. Comparatively, 55.6% of Interparfums shares are held by institutional investors. 1.4% of Prestige Consumer Healthcare shares are held by insiders. Comparatively, 43.9% of Interparfums shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Interparfums beats Prestige Consumer Healthcare on 11 of the 19 factors compared between the two stocks.
Get Prestige Consumer Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Prestige Consumer Healthcare Competitors List
Related Companies and Tools
This page (NYSE:PBH) was last updated on 7/15/2025 by MarketBeat.com Staff